By Lucy Parkinson, VP of Investor Research, LSN
In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This RESI Boston panel will feature five speakers and a moderator from various big pharma companies discussing topics such as:
- How big pharma sources assets
- The evaluation and investment process
- Key factors of interest
- How early-stage big pharma is willing to look
At RESI Boston on September 6th, we welcome five speakers from major pharma firms who will explain how they evaluate early stage companies for potential licensing and partnership relationships. The panelists are:
- Alex Rabiee, Director, Business Development, Amgen
- Lizabeth Leveille, Head, Boston Innovation Hub, Merck
- Imran Nasrullah, Director, BD&L, Strategic Partnering, Boehringer Ingelheim
- Niels Emmerich, Senior Director, Global Head Search & Evaluation Oncology, AbbVie
- Tim Luker, VP External Innovation, Eli Lilly
These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.
Leave a Reply